Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(4-chlorophenyl)-adamantane-1-carboxylic Acid (pyridin-4-ylmethyl)amide
2. 4-pyridinylmethyl-3-(4-chlorophenyl) Adamantane Carboxamide
3. Abc 294640
4. Abc-294640
5. Abc294640
1. Abc294640
2. Opaganib
3. 915385-81-8
4. Abc-294640
5. Abc 294640
6. Chembl2158685
7. 4-pyridinylmethyl-3-(4-chlorophenyl) Adamantane Carboxamide
8. Drg21oq517
9. Yeliva
10. Tricyclo(3.3.1.13,7)decane-1-carboxamide, 3-(4-chlorophenyl)-n-(4-pyridinylmethyl)-
11. Abc294640opaganib
12. Opaganib [inn]
13. Opaganib [who-dd]
14. Opaganib (abc294640)
15. Gtpl6624
16. Schembl1548333
17. Chebi:124965
18. Dtxsid801318727
19. Hms3402p05
20. Amy42174
21. Bcp08959
22. Ex-a1962
23. Bdbm50393642
24. Nsc796101
25. Akos027327311
26. Ccg-268417
27. Cs-0877
28. Db12764
29. Nsc-796101
30. Sb17167
31. Ac-33116
32. As-56117
33. Ba162479
34. Hy-16015
35. S7174
36. Brd-a70814879-003-01-8
37. Q27074100
38. Abc294640
39. 915385-81-8
40. Abc-294640
41. 4-pyridinylmethyl 3(4-chlorophenyl)adamantine Carboxamide
42. (1s,3r,5r,7s)-3-(4-chlorophenyl)-n-(pyridin-4-ylmethyl)adamantane-1-carboxamide
| Molecular Weight | 380.9 g/mol |
|---|---|
| Molecular Formula | C23H25ClN2O |
| XLogP3 | 4.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 380.1655411 g/mol |
| Monoisotopic Mass | 380.1655411 g/mol |
| Topological Polar Surface Area | 42 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 551 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Opaganib selectively inhibits [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0). This inhibition blocks the synthesis of sphingosine 1-phosphate (S1P) and its activities (which includes regulation of fundamental biological processes such as cell proliferation, migration, immune cell trafficking, angiogenesis, immune-modulation, and suppression of innate immune responses from T-cells). This drug has dual anti-inflammatory and antiviral activity targeting a host cell component and is unaffected by viral mutation, contributing to minimization of the likelihood of resistance. It is currently being investigated against COVID-19 as it has demonstrated anti-SARS-CoV-2 activity in studies.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
64
PharmaCompass offers a list of Opaganib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Opaganib manufacturer or Opaganib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Opaganib manufacturer or Opaganib supplier.
PharmaCompass also assists you with knowing the Opaganib API Price utilized in the formulation of products. Opaganib API Price is not always fixed or binding as the Opaganib Price is obtained through a variety of data sources. The Opaganib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Opaganib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Opaganib, including repackagers and relabelers. The FDA regulates Opaganib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Opaganib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Opaganib supplier is an individual or a company that provides Opaganib active pharmaceutical ingredient (API) or Opaganib finished formulations upon request. The Opaganib suppliers may include Opaganib API manufacturers, exporters, distributors and traders.
Opaganib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Opaganib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Opaganib GMP manufacturer or Opaganib GMP API supplier for your needs.
A Opaganib CoA (Certificate of Analysis) is a formal document that attests to Opaganib's compliance with Opaganib specifications and serves as a tool for batch-level quality control.
Opaganib CoA mostly includes findings from lab analyses of a specific batch. For each Opaganib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Opaganib may be tested according to a variety of international standards, such as European Pharmacopoeia (Opaganib EP), Opaganib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Opaganib USP).
